Souhaitez-vous accéder aux communiqués récents ?

U.S. FDA Accepts Shire's Biologics License Application for Calaspargase Pegol (Cal-PEG) for Acute Lymphoblastic Leukemia (ALL) If approved, Cal-PEG could provide a new PEGylated...

The European Medicines Agency (EMA) Grants Accelerated Assessment for Shire's Lanadelumab Being Evaluated for the Prevention of Attacks in Hereditary Angioedema (HAE) Patients Aged 12 Years and Older ...

FDA Accepts Shire's Biologics License Application (BLA) and Grants Priority Review for Lanadelumab for the Prevention of Attacks in Hereditary Angioedema (HAE) Patients -       Lanadelumab, the...

Shire Recognizes Rare Disease Day 2018 with Global Initiatives Focused on Reducing the Time to Diagnosis Diagnosis is one of the most important issues affecting health, longevity and well-being...

Shire to Present Data at 2018 AAAAI/WAO Joint Congress Demonstrating Commitment to Ongoing Research and Innovation in Rare Immune Conditions Hereditary angioedema (HAE) and primary...

Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases Alliance aims to shorten the often multi-year journey that patients and families...

**CORRECTION - Shire Announces FDA Acceptance of sBLA for CINRYZE® (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use FDA assigns an action date of June 20, 2018 If...

Director/PDMR Shareholding February 15, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") Notification of transactions by person discharging managerial responsibilities 1. Details of the...

Shire Announces FDA Acceptance of sBLA for CINRYZE® (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use FDA assigns an action date of June 20, 2018 If approved, CINRYZE...

Shire reports 8% pro forma product sales and strong earnings growth resulting in record operating cash flow for full year 2017 Strong growth driven by Immunology, recently launched products, and...